The Role of Statistics in Regulatory Decision Making

Lisa M. LaVange

Type: Article

Publication Date: 2013-12-30

Citations: 20

DOI: https://doi.org/10.1177/2168479013514418

View

Locations

Therapeutic Innovation & Regulatory Science - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+	Promoting the Science of Regulatory Statistics in Support of Regulatory Decisionmaking	2013	Robert T. O’Neill
+	The future of statistics and statisticians in European regulatory affairs	1992	David R. Jones
+	DECISIONS IN STATISTICS	2009
+ PDF Chat	Statistics in Therapeutic Innovation and Regulatory Decision Making	2013	J. Rick Turner
+	The Role of Statistics	1964	W. J. Jennett
+	The Role of Statistics	2003	Joshua Fox
+	Statistics: Decisions and applications in business and economics	1982	Peter E. Nuesch
+	Role Of Statistics In Public Policy Formulation	2018	Prakash Maniar
+ PDF Chat	Statistics for Making Decisions,	2022	Angelika Marlene Stefan
+	Role of Statistics.	2011	Ashok Sahai Miodrag Lovrić
+	Statistics as a tool for decision-making: Two countries and one pattern	2018	Raimundo Elicer Vanessa Franco Neto
+	Decision-Making and Statistical Standards	1965	James E. Webb
+	Statistical Decision-Making	2021	Michael F. Insana
+	STATISTICAL MODELING AND DECISION SCIENCE	1990
+	STATISTICAL MODELING AND DECISION SCIENCE	1994
+	STATISTICAL MODELING AND DECISION SCIENCE	1989
+	STATISTICAL MODELING AND DECISION SCIENCE	1990
+	STATISTICAL MODELING AND DECISION SCIENCE	1990
+	STATISTICAL MODELING AND DECISION SCIENCE	1994
+	STATISTICAL MODELING AND DECISION SCIENCE	1991

Cited by (16)

Action	Title	Year	Authors
+	Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials	2022	Mallorie H. Fiero Jessica Roydhouse Vishal Bhatnagar Ting‐Yu Chen Bellinda L. King‐Kallimanis Shenghui Tang Paul G. Kluetz
+	Making what’s advanced today routine tomorrow	2015	Stephen J. Ruberg
+ PDF Chat	Estimation of treatment effects in short‐term depression studies. An evaluation based on the <scp>ICH E9</scp>(<scp>R1</scp>) estimands framework	2022	Marian Mitroiu Steven Teerenstra Katrien Oude Rengerink Frank Pétavy Kit C. B. Roes
+	Methods for efficacy evaluations of antibacterial treatments in multiple body-site infection trials	2016	Mohammad F. Huque Thamban Valappil Mohamed Alosh Guoxing Soon
+	Authors' response to comments	2016	Péter Bauer Frank Bretz Vladimir Dragalin Franz König Gernot Wassmer
+	Properties of adaptive clinical trial signature design in the presence of gene and gene-treatment interaction	2017	A. Cambon Kathy B. Baumgartner Guy Brock Nigel G. F. Cooper David Wu S. N.
+	Biostatistics in Clinical Trials	2020	Olga Marchenko Lisa M. LaVange Natallia Katenka
+ PDF Chat	The Role of Expert Judgment in Statistical Inference and Evidence-Based Decision-Making	2019	Naomi C. Brownstein Thomas A. Louis Anthony O’Hagan Jane Pendergast
+ PDF Chat	Leadership in Statistics: Increasing Our Value and Visibility	2017	Eric W. Gibson
+	Mixed-effects Models for Repeated Measures in Longitudinal Data Analysis: An Introduction to Methodology, Theory, and Applications	2017	Masahiko Gosho Kazushi Maruo
+	Estimands in clinical drug development: from design to regulatory assessment	2022	Marian Mitroiu
+	Discussion on “Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes” by David Benkeser, Ivan Diaz, Alex Luedtke, Jodi Segal, Daniel Scharfstein, and Michael Rosenblum	2021	Lisa M. LaVange
+	Hierarchical nested trial design (HNTD) for demonstrating treatment efficacy of new antibacterial drugs in patient populations with emerging bacterial resistance	2014	Mohammad F. Huque Thamban Valappil Guoxing Soon
+	Commentary on “Statistics at FDA: Reflections on the Past Six Years”	2019	Olga Marchenko
+	Statistics at FDA: Reflections on the Past Six Years	2019	Lisa M. LaVange
+	Consistency ensured test strategies for supportive evidence of treatment efficacy in noninferiority clinical trials	2017	Mohammad F. Huque Thamban Valappil Mohamed Alosh

Citing (15)

Action	Title	Year	Authors
+	Encyclopedia of Biopharmaceutical Statistics	2010	Shein‐Chung Chow
+	BIOPHARMACEUTICAL STATISTICS IN A PHARMACEUTICAL REGULATED ENVIRONMENT: PAST, PRESENT, AND FUTURE	2001	Anthony C. Segreti Hoi M. Leung Gary G. Koch Robert L. Davis Noel R. Mohberg Karl E. Peace
+	Similarities and Differences of Bayesian Designs and Adaptive Designs for Medical Devices: A Regulatory View	2013	Gregory Campbell
+ PDF Chat	Adaptive adjustment of the randomization ratio using historical control data	2013	Brian P. Hobbs Bradley P. Carlin Daniel J. Sargent
+ PDF Chat	The Prevention and Treatment of Missing Data in Clinical Trials	2012	Roderick J. A. Little Ralph B. D’Agostino Michael L. Cohen Kay Dickersin Scott S. Emerson John T. Farrar Constantine Frangakis Joseph W. Hogan Geert Molenberghs Susan A. Murphy
+ PDF Chat	Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies	2010	Christy Chuang‐Stein Mohan Beltangady
+	Bayesian approach to the design and analysis of non‐inferiority trials for anti‐infective products	2013	Meg A. Gamalo Ram C. Tiwari Lisa M. LaVange
+	Bayesian Statistics in Medical Devices: Innovation Sparked by the FDA	2011	Gregory Campbell
+	Bayesian Approach for Clinical Trial Safety Data Using an Ising Prior	2013	Bradley McEvoy Rajesh Nandy Ram C. Tiwari
+	Multiplicity in Regulatory Statistical Review	2013	Thomas Permutt
+	A statistical approach to central monitoring of data quality in clinical trials	2012	David Venet Erik Doffagne Tomasz Burzykowski F. Beckers Yves Tellier Eric Genevois-Marlin Ursula Becker Valerie Bée Véronique Wilson Catherine Legrand
+ PDF Chat	The Prevention and Treatment of Missing Data in Clinical Trials	2010	National Research Council
+	P-Values, Evidence, and Multiplicity Considerations for Controlled Clinical Trials	2010	Mohammad F. Huque Mohamed Alosh Satya D. Dubey Rafia Bhore
+	Career success training for statisticians: a progress update	2012	Robert M. Rodriguez
+	P-Values, Evidence and Multiplicity Considerations for Controlled Clinical Trials	2003	Mohammad F. Huque Mohamed Alosh S. D. Dubey